# MapLight Therapeutics Posts $0.97 Q3 GAAP Loss Per Share, Beats Estimates

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58567
Published: 2026-11-16T15:47:11.000Z
Updated: 2026-11-16T15:47:11.000Z
Section: Business

> MapLight Therapeutics, Inc. had $463.4 million in cash, cash equivalents and investments as of Sept. 30.

MapLight Therapeutics, Inc. posted a third-quarter GAAP loss of $0.97 per share, beating estimates by $0.22.

The company had $463.4 million in cash, cash equivalents and investments as of Sept. 30, 2026.


